• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BioDelivery Sciences to Report Third Quarter 2021 Financial Results on November 3, 2021

    10/20/21 8:00:00 AM ET
    $BDSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BDSI alert in real time by email

    RALEIGH, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it will report its third quarter 2021 financial results before the open of the U.S. financial markets on Wednesday, November 3, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

    Conference Call Dial-In & Webcast Information:

    Date: Wednesday, November 3, 2021
    Time:8:30 AM Eastern Time
    Domestic:877-407-0789
    International:201-689-8562
    Conference ID:13723637
    Webcast:http://public.viavid.com/index.php?id=146730

    ABOUT BIODELIVERY SCIENCES INTERNATIONAL, INC.

    BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.

    © 2021 BioDelivery Sciences International, Inc.  All rights reserved.

    Contact:

    Bob Yedid

    LifeSci Advisors

    646-597-6989

    [email protected]



    Primary Logo

    Get the next $BDSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDSI

    DatePrice TargetRatingAnalyst
    2/15/2022$5.00 → $5.60Overweight → Neutral
    Piper Sandler
    1/21/2022$4.00 → $4.50Neutral
    HC Wainwright & Co.
    11/4/2021$6.00 → $4.50Buy → Neutral
    HC Wainwright & Co.
    8/5/2021$5.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BDSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genenta Provides First Half 2022 Business Update and Financial Results

      Current dose escalation study data shows a median overall survival of 17 monthsAdding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7 million as of June 30, 2022, providing a cash runway until the end of 2024€1.8 million unrealized foreign exchange gain MILAN, Italy and NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), ("Genenta" or the "Company"), a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, provides business and financial results for the six months ended June 30, 2022.

      10/24/22 7:30:00 AM ET
      $GNTA
      $BDSI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Genenta Announces Nomination of Mark A. Sirgo as Chair

      35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over 35 years of pharmaceutical industry experience, as its new Chair. Stephen Squinto, PhD is stepping down from his role as Chair on May 1, 2022 to pursue a new business opportunity. Dr. Sirgo most recently was CEO of Aruna Bio, Inc., a preclinical biotech compan

      4/27/22 7:30:00 AM ET
      $BDSI
      $GNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Collegium Completes the Acquisition of BDSI

      STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) ("Collegium") today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (NASDAQ:BDSI) ("BDSI"). "This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "We have significantly diversified the business and expanded our overall revenue scale. This transaction is immediately and highly accretive, and we are now focused on seamless integratio

      3/22/22 5:01:00 PM ET
      $BDSI
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioDelivery Sciences Intl downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded BioDelivery Sciences Intl from Overweight to Neutral and set a new price target of $5.60 from $5.00 previously

      2/15/22 4:35:51 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on BioDelivery Sciences Intl with a new price target

      HC Wainwright & Co. reiterated coverage of BioDelivery Sciences Intl with a rating of Neutral and set a new price target of $4.50 from $4.00 previously

      1/21/22 6:26:41 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioDelivery Sciences Intl downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded BioDelivery Sciences Intl from Buy to Neutral and set a new price target of $4.50 from $6.00 previously

      11/4/21 7:12:11 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Watson W. Mark disposed of 90,663 shares, closing all direct ownership in the company to satisfy tax liability

      4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)

      3/22/22 5:18:46 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vollins James (withholding tax)

      4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)

      3/22/22 5:18:09 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Singh Vanila disposed of 35,851 shares, closing all direct ownership in the company to satisfy withholding tax

      4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)

      3/22/22 5:17:22 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by BioDelivery Sciences International Inc. (Amendment)

      SC 13G/A - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)

      2/10/23 4:14:56 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by BioDelivery Sciences International Inc.

      SC 13D - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)

      2/24/22 12:05:58 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by BioDelivery Sciences International Inc.

      SC 13G - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)

      2/24/22 11:06:16 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    SEC Filings

    See more
    • SEC Form 15-12B filed by BioDelivery Sciences International Inc.

      15-12B - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)

      4/1/22 5:02:37 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by BioDelivery Sciences International Inc.

      EFFECT - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)

      3/28/22 12:15:08 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by BioDelivery Sciences International Inc.

      S-8 POS - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)

      3/23/22 5:30:38 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Leadership Updates

    Live Leadership Updates

    See more
    • BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer

      RALEIGH, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial Officer, effective November 4, 2021.  Mr. Golubieski brings to BDSI more than 30 years of financial and operational experience and will serve as a member of the company's executive leadership team. "I'm pleased to welcome John to our executive leadership team. His appointment comes at a time of significant opportunity and growth for BDSI," said Jeff Bailey, Chief Executive Officer. "I know first-h

      10/21/21 8:00:00 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

      BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an

      8/16/21 8:00:00 AM ET
      $AZRX
      $BCPC
      $BDSI
      Major Pharmaceuticals
      Health Care
      Major Chemicals
      Industrials

    $BDSI
    Financials

    Live finance-specific insights

    See more
    • Collegium Completes the Acquisition of BDSI

      STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) ("Collegium") today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (NASDAQ:BDSI) ("BDSI"). "This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "We have significantly diversified the business and expanded our overall revenue scale. This transaction is immediately and highly accretive, and we are now focused on seamless integratio

      3/22/22 5:01:00 PM ET
      $BDSI
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio

      - Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million - - Will Diversify Revenue Growth and Accelerate Cash Flow Generation - - Addition of BELBUCA® Provides a Second Growth Driver and ELYXYB™ Establishes Foothold in Neurology - - Conference Call Scheduled for Today at 8:30 a.m. ET - STOUGHTON, Mass. and RALEIGH, N.C., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) and BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash. BDSI has a portfolio of pain and neurology products that addre

      2/14/22 6:30:00 AM ET
      $BDSI
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioDelivery Sciences Reports Solid Third Quarter 2021 Results

      Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07, EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential long-term peak sales opportunity of $350 - $400 million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported solid financial results for the third quarter ended

      11/3/21 8:00:00 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care